Alkermes (ALKS) Invested Capital (2011 - 2026)

Alkermes (ALKS) posted quarterly Invested Capital of $26.5 million for Q2 2026, little changed quarter-over-quarter from $26.5 million in Q1 2026.

Alkermes (ALKS) Invested Capital (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Invested Capital for 15 consecutive years, with $26.5 million the latest figure, recorded in Q2 2026.

In Q2 2026, Invested Capital changed N/A year-over-year to $26.5 million; the TTM figure through Jun 2026 stood at $53.0 million (up 1666.67% YoY), while the FY2023 annual figure was $3.0 million, changed 0.0% from the prior year.
Invested Capital steadied at $26.5 million in Q2 2026 per ALKS's latest filing, from $26.5 million in the prior quarter.
Across five years, Invested Capital topped out at $26.5 million in Q1 2026 and bottomed at $3.0 million in Q1 2022.
Historically, Invested Capital has averaged $6.6 million across 4 years, with a median of $3.0 million in 2022.
On a YoY basis, Invested Capital climbed as much as 0.0% in 2022 and fell as far as 0.0% in 2022.
Alkermes' Invested Capital stood at $3.0 million in 2022, then changed by 0.0% to $3.0 million in 2023, then changed by 0.0% to $3.0 million in 2024, then soared by 783.33% to $26.5 million in 2026.
Business Quant data shows ALKS's Invested Capital at $26.5 million in Q2 2026, $26.5 million in Q1 2026, and $3.0 million in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	9.90 Bn
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	4.50 Bn
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	3.74 Bn
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	-
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	1.74 Bn
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	-
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	73.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	630.00 Mn
10	Alkermes	8.07 Bn	7.41 Bn	397.90 Mn	26.50 Mn

Download Data